The FDA has lifted the partial clinical hold on Vigil Neuroscience’s Phase I trial of VG-3927, a novel treatment for neurodegenerative diseases linked to microglial dysfunction, particularly Alzheimer’s disease. The decision follows a complete response submitted by Vigil Neuroscience to the regulator.
Promising Early Data
Interim findings from the single- and multiple-ascending dose study of VG-3927 in healthy subjects, shared in July, demonstrated that the drug is suitable for further clinical exploration based on safety and tolerability data from six SAD and two MAD cohorts. The pharmacokinetic profile supported the potential for once-daily dosing. VG-3927 also showed promising signs of efficacy, including a sustained decline in soluble TREM2 levels in the cerebrospinal fluid (CSF), providing clinical evidence of target engagement. An increase in osteopontin/secreted phosphoprotein 1 (SPP1) was also observed after repeated doses of the treatment.
Expansion to Alzheimer's Patients
The ongoing Phase I trial has now expanded to include patients suffering from Alzheimer’s disease, some of whom have TREM2 or other disease-related genetic variations. This cohort will help assess VG-3927’s biomarker response after a single dose.
Future Plans
Vigil Neuroscience aims to release the complete Phase I data, including results from the Alzheimer’s patient cohort, in the first quarter of next year.
About VG-3927
VG-3927 is a small molecule TREM2 agonist being developed to address neurodegenerative diseases linked to microglial dysfunction, initially focusing on treating Alzheimer’s disease.
Executive Perspective
Vigil Neuroscience chief medical officer Petra Kaufmann said, “We are pleased with the resolution of the partial clinical hold, a decision that was supported by non-clinical and clinical data from our ongoing Phase I trial. While the partial clinical hold did not delay the clinical development of VG-3927, the option to increase the exposure limit provides us the best opportunity to explore the full pharmacology of VG-3927 as a potentially novel, next-generation therapy for those living with Alzheimer’s disease.”
